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ABSTRACT
Prolonged exposure to estrogens is considered a major risk factor for development of breast cancer. When treated with the naturally occurring estrogen, 17β-estradiol, ACI rats develop mammary cancers in over 90% of the population at risk. Genetic crosses between the susceptible ACI rat and resistant Copenhagen (COP) or Brown Norway (BN) rats identified a region on chromosome 5 (Emca1) that modified the development of estrogen-induced mammary cancer. The purpose of this research is to determine the role of Emca1 in the development of mammary cancer. To define the role of Emca1 in the development of mammary cancer, a congenic line was developed (ACI.BN-Emca1) in which the resistant BN allele of Emca1 was introgressed onto an ACI background. To determine the number of modifiers that reside within Emca1, four additional congenic lines that encompass overlapping regions of RNO5 within the Emca1 region were developed. Characterization of these congenic lines indicated that at least three modifiers of estrogen-induced mammary cancer reside within Emca1. Analysis of microarray data identified ten genes that may modify estrogen-induced mammary cancer within Emca1.
SUBJECT TERMS
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BODY:
The following accomplishments are documented according to the approved statement of work:
Task 1: Evaluate the impact of Emca1 on the development of estrogen-induced mammary cancer. This task was completed in the second year of the grant.
•Results: ACI.BN-Emca1 (Emca1) rats exhibited increased latency to the development of estrogen-induced mammary cancer and decreased incidence in the population at risk ( Figure 1A ). In addition, Emca1 rats developed significantly fewer mammary tumors than ACI rats ( Figure 1B ). However, there was no difference in the gross appearance of the mammary tissue from ACI and Emca1 rats following 12 weeks of estrogen treatment (Figure 2 ), suggesting that Emca1 does not affect the proliferative response of the mammary gland to estrogen. Instead, Emca1 appears to delay the transformation of mammary hyperplasia to mammary cancer.
•Status: Completed Task 2: Establish more precisely the location of the genes that confer and/or modify susceptibility to estrogen-induced mammary cancer.
Because additional genotyping and statistical analysis did not provide insight into regions on chromosome 5 that could modify estrogen-induced mammary cancer, these analyses were not utilized to more precisely define the genes within the Emca1 locus that modify susceptibility to estrogen-induced mammary cancer. Instead, microarray analysis of 12 week estrogen-treated mammary tissue was utilized to determine changes in gene expression and to identify genes within the Emca1 locus that are differentially regulated by estrogen. During this reporting period, microarray data were analyzed using Gene Chip Operating Software (GCOS) and dCHIP software.
•Experimental Design: Total RNA was isolated from approximately 40 mg of 12 week E2-treated mammary tissue from ACI (5) and Emca1(5) female rats using the Absolutely RNA miniprep kit from Stratagene. Two micrograms of RNA was labeled and hybridized to the Affymetrix Rat 230 2.0 microarray by personnel in the UNMC Microarray Core Facility.
•Results: GCOS was used to assess the data quality. Data from all five ACI and Emca1 microarray data sets were within the recommended quality control parameters. dChip was used to normalize all arrays and to identify differentially expressed genes. Genes were identified as differentially expressed if 1) the fold change was ≥ 1.5; 2) the absolute difference of the group means was ≥ 100; 3) the T-test P value was ≤ 0.05; and 4) the gene was present in at least 20% of the samples. Data sets were also selected in which genes were present in one group of samples and absent in the other group of samples. Table 1 summarizes the changes in gene expression identified in these comparisons. Of the forty genes differentially expressed, eleven of the genes resided on RNO5 within the Emca1 region. Ten additional genes were considered present in the ACI and absent in the Emca1. Of these ten genes, four resided on RNO5 within the Emca1 region. A list of these 15 genes is included Table 2 . These analyses indicate that 1) genes within Emca1 are differentially expressed after 12 weeks of estrogen treatment; and 2) the Emca1 region on RNO5 modifies the expression of other genes outside the congenic interval. Thus, these analyses provide important tools to identify genes, both globally and within Emca1, that are differentially expressed as a result of estrogen treatment. Quantitative real-time PCR is underway to verify the differential expression of five selected genes. • Status: This task is completed.
Table2. Genes differentially expressed in
Task 3: Characterize additional congenic lines carrying specific intervals of Emca1 to determine the effect of genotype on susceptibility to estrogen-induced mammary cancer.
• Analysis of the pattern of LRS peaks during the progression of mammary identified three potential regions of interest on RNO5. In addition, cdkn2a was identified as a potential candidate because the gene is located at the peak LRS value shown in Figure 3 and a congenic line was developed that contained approximately 8 million base pairs (Mb) of BN RNO5 introgressed onto an ACI background. During this reporting period, the impact of estrogen-induced mammary cancer was characterized in these four additional congenic lines.
• Experimental Design: Treat females from the four Emca1 congenic sublines (Emca1a, Emca1b, Emca1c, and Emca1-p16 (Figure 3 ) with estrogen for 28 weeks beginning at nine weeks of age. Figure 3 . Boundaries of the four Emca1 congenic sublines. The Emca1 locus has been divided and multiple congenic lines developed to better define the region of interest on RNO5. Lines represent the region on RNO5 encompassed by the congenic sublines.
• Results: The four additional congenic lines exhibited a significant increase in latency to the development of mammary cancer (Figure 4 ) compared to ACI rats, but were not significantly different from the Emca1 rats. In addition, Emca1b and Emca1c rats also exhibited a decreased incidence of mammary cancer in the population at risk that was similar to Emca1 rats. Figure 4 . Impact of estrogen on development of mammary cancer in Emca1 congenic sublines. ACI, Emca1a, Emca1b, Emca1c and Emca1-p16 rats were treated with estrogen beginning at nine weeks of age. Rats were sacrificed following 28 weeks of estrogen treatment or when necessary due to treatment related morbidity. Kaplan-Meier survival analysis of the Emca1 congenic sublines. The combined ACI and Emca1 survival curve are depicted for comparison purposes. * Indicates a significant difference in the congenic lines compared to the ACI. Figure 5 . Impact of estrogen on the number of mammary cancers in Emca1 congenic sublines. The number of tumors at necropsy was analyzed for the rats in Figure 4 above. Rats treated with estrogen for less than 196 days were not included in this analysis. Rats treated with estrogen for 196 days that were mammary cancer negative at necropsy were given a tumor number of zero. Mean mammary cancers ± the standard error of mean (SEM) at necropsy for ACI (77), Emca1 (39), Emca1a (28), Emca1b (33), Emca1c (30) and Emca1-p16 (18) rats is shown. * Indicates a significant difference in the congenic lines The number of mammary cancers per rat in the Emca1a, Emca1b, and Emca1c congenic Status: This task is completed.
EY RESEARCH ACCOMPLISHMENTS:
• Analysis of the proliferative response to estrogen of the Emca1, Emca1a, Emca1b, in the ACI.BN-Emca1 congenic line compared genes/ESTs that are differentially expressed in 12 week estrogenlines differed significantly from the number of mammary cancers in the ACI rat, but did not differ significantly from the number of mammary cancers in the Emca1 rats. Although the Emca1-p16 rats exhibited a significant decrease in the latency to the development of mammary cancers, the average number of mammary cancers per rat was significantly increased compared to the Emca1, Emca1a, Ecma1b and Emca1c rats, but did not differ significantly from the parental ACI rats, indicating that this region on RNO5 delays the development of mammary cancers, but does not impact mammary cancer multiplicity. When treated with estrogen, ACI rats also develop pituitary hyperplasia commonly referred to as pituitary tumors. We have mapped the regions of the rat genome associated with estrogen-induced pituitary hyperplasia. Although RNO5 has not been associated with a pituitary phenotype in the ACI rats, the Emca1-p16 rats exhibited an extreme pituitary phenotype that was not exhibited by the Emca1, Emca1a, Emca1b or Emca1c congenic lines, suggesting that this region of RNO5 could harbor a regulator of estrogen-induced pituitary growth that is suppressed in the other four congenic lines. These data indicate that at least two strong and one weak modifier of esstrogen-induced mammary cancer reside within the Emca1 locus on RNO5.
• K Emca1c, and Emca1-p16 congenic lines.
• Analysis of changes in gene expression to the parental ACI.
• Identification of 15 treated mammary tissue of Emca1 rats compared to ACI rats. 
CONCLUSIONS:
The Emca1, Emca1a to Emca1c congenic lines also exhibited decreased incidence within the population at risk and decreased tumors per rat when compared with the susceptible ACI parental rats indicating that at least three modifiers of estrogen-induced mammary cancer reside within the Emca1 locus on RNO5. Of the 15 genes that were differentially expressed between the Emca1 and ACI rats, four genes did not reside within any of the Emca1 sublines and are not potential candidate genes for the Emca1 region on RNO5 (Table 2) . Multiple candidate genes were identified for the Emca1a, Emca1b and Emca1c congenic sublines (Table 2) . Because the regions of RNO5 encompassed by Emca1a and Emca1c do not overlap, these congenic lines must contain different modifiers of estrogen-induced mammary cancer. Potential candidate genes for Emca1a include a transcribed sequence with similarity to the human ATP binding cassette gene, a transcribed sequence similar to hypothetical protein D4Ertd765e, a sequence similar to nbla10363, and a transcribed sequence on which little is known. Potential candidates for Emca1c include a protein similar to CD2-associated protein, the zinc finger protein pMLZ-4, a taste receptor, a protein similar to 2610027C15Rik, and a transcribed sequence. The region of RNO5 that encompasses the Emca1b congenic line overlaps with Emca1a, Emca1c and may harbor both the Emca1a and Emca1c modifiers of E2-induced mammary cancer. However, the region of Emca1b that does not overlap with either Emca1a or Emca1c encompasses the Pde4b gene that has been shown to be overexpressed in breast cancer and is a strong candidate gene for estrogen-induced mammary cancer. Thus, it is possible that Emca1a, Emca1b and Emca1c each contain different modifiers of estrogen-induced mammary cancer. No gene that was differentially expressed resided within the Emca1-p16 congenic line suggesting that an additional modifier(s) of estrogen-induced mammary cancer is yet to be identified. A search of genes resident on RNO5 using NCBI Map Viewer indicated that 64 genes or predicted genes reside within the Emca1-p16 region between 106.29 and 114.80 Mb. Both the cdkn2a and cdkn2b genes, which reside within this region, were below the level of sensitivity of the microarray analysis and are considered good candidates for the Emca1-p16 congenic line. Expression of these genes is being analyzed by another member of the lab and was not presented here. Preparation of a manuscript that describes these results is currently underway. In summary, we have shown that Emca1 contains at least three modifiers of estrogen-induced mammary cancer. We have also identified potential candidate genes for Emca1, but additional research is required to verify the role of these genes in estrogen-induced mammary cancer in the ACI rat.
